Manufacturing the Future: Overcoming Scale-up Challenges for HS...

добавлена новая статья Health

2025-12-26 09:48:05 -

Manufacturing the Future: Overcoming Scale-up Challenges for HS Biologics

Why is the manufacturing of HS therapies a strategic bottleneck? HS biologics are often required in higher doses than those used for psoriasis or rheumatoid arthritis. This creates a unique challenge for manufacturing and supply chain management: producing massive quantities of high-purity proteins while maintaining cost-efficiency. A company’s "Capacity to Scale" is now just as important...

0 Комментарии 0 Поделились 101 Просмотры 0 предпросмотр